JYNT · The Joint Corp.

The Joint Corp. reported first quarter 2026 results that reflect progress in its refranchising strategy and improved profitability. Revenue from continuing operations grew 13% year-over-year to $14.8 million, driven by the early benefits of refranchising and portfolio optimization. Consolidated net income increased 34% to $1.3 million, while Adjusted EBITDA from continuing operations swung from $46,000 to $2.2 million. The company reiterated its 2026 guidance, expecting system-wide sales between $519 million and $552 million and consolidated Adjusted EBITDA of $12.5 million to $13.5 million. Management highlighted the near-completion of the Joint 2.0 refranchising initiative, with only three company-owned clinics expected after pending sales. The company also entered into a waiver and fourth amendment to its credit agreement with JPMorgan Chase, waiving a prior default and extending the maturity to August 2029, while adding a minimum liquidity covenant. During the quarter, the company repurchased 137,000 shares for $1.1 million, with $4.5 million remaining under its buyback program. The combination of improved financial results, strengthened balance sheet, and extended credit facility positions the company for its next growth phase, Joint 3.0, focusing on new channels and brand activation.